DIAGNOS Announces a Pilot with Opticalia in Spain
July 28 2021 - 8:05AM
Diagnos Inc. (“
DIAGNOS” or the
“
Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA:
4D4A), a leader in early detection of critical health issues,
announces today the signing of a pilot in Spain with three
franchisees from Opticalia Group.
“A proposal that combines optometrist knowledge,
telemedicine and artificial intelligence to obtain fast results,
without invasive methodology and with totally reliable results. A
smart retinography is also used which, once the patient is
positioned, it automatically searches for the retina in the eye.
All the techniques used in this process are non-invasive, painless
and quick for the comfort and tranquility of the patient,” states
Mrs. Elsa Tortosa, owner and head of optometrists in Opticalia
franchise in Pinoso, Spain.
Meanwhile in the cities of Aspe and Novelda,
Spain, Mr. Santos Díaz, head of optometrists and owner of
franchises Opticalia, who has been in the sector for 23 years
innovating and transforming his optics into the new business model
oriented to health in general and visual in particular, says “The
campaign begins with the request for a previous appointment through
the web or at the optician itself, where patients will register in
order of arrival and a free retinography will be carried out. With
the results we obtain, a pre-diagnosis of their fundus will be made
with respect to diabetic retinopathy.”
The Councillor for Health in the Aspe City
Council, Mrs. Yolanda Moreno, stressed that this initiative will
produce important data concerning the eye health for all Aspenses.
“Thanks to Opticalia Aspe our neighbors will be able to benefit
from a treatment pre-diagnosis that allows detection of visual
problems in a timely manner.”
Opticalia Aspe is investing, on its own
initiative, 6,000 euros in this campaign to detect and stop
preventable blindness.
“One of the tools used in this diagnostic
process is based on artificial intelligence, a resource that comes
from DIAGNOS, an international company located in Canada with
extensive experience and with more than 400 thousand retinographies
performed around the world. This allows the precision of diabetic
retinopathy pre-diagnoses to be very high, reaching a Sensitivity
of 98.4%, Specificity of 97.6% and a Certainty of 97.9%. Data that
improves human diagnoses under the same conditions, without
applying drops to dilate the pupil and in 4 seconds, which is known
as non-mydriatic retinography,” said Mr. Andre Larente,
President of DIAGNOS.
About OpticaliaOpticalia was
founded as a great image group 10 years ago in Spain. Our goal is
to group independent opticians who, while maintaining their
personality, benefit from the advantages generated by belonging to
a recognized brand. More than 1,000 opticians associated and
trusting in Opticalia in 5 countries give us the size to obtain
negotiating advantages: Spain and 4 attached plants in Portugal,
Mexico, Colombia and Morocco. Services designed so that all
opticians associated with Opticalia have competitive advantages
that help them manage their business and be competitive against
chains and future operators in the sector.
About DIAGNOSDIAGNOS is a
publicly traded Canadian corporation dedicated to early detection
of critical health problems based on its FLAIRE Artificial
Intelligence (AI) platform. FLAIRE allows for quick modifying and
developing of applications such as CARA (Computer Assisted Retina
Analysis). CARA’s image enhancement algorithms provide sharper,
clearer and easier-to-analyze retinal images. CARA is a
cost-effective tool for real-time screening of large volumes of
patients. CARA has been cleared for commercialization by the
following regulators: Health Canada, the FDA (USA), CE (Europe),
COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).
Additional information is available
at www.diagnos.com and www.sedar.com.
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Corporate Communications:
Nancy Massicotte
IR Pro Communications Inc.
Dir: +1 604-507-3377
TF: 1-866-503-3377
Email: nancy@irprocommunications.com
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024